🏥 Medicine & Health

Intracortical brain-computer interfaces now decode intended speech at rates approaching natural conversation—in English and, for the first time, in tonal languages like Chinese. But the gap between laboratory performance and daily-use reliability remains substantial.

Merlin, a CT vision-language model trained on 15,000+ CT scans with paired radiology reports, achieves 118 citations by demonstrating that foundation models can interpret abdominal CT at clinically useful accuracy. But the explainability gap and demographic biases in training data remain unresolved.

Medical AI achieves radiologist-level accuracy on narrow tasks—but clinicians don't trust what they can't understand. A framework distinguishing transparency, interpretability, and explainability reveals why current XAI methods fall short of clinical needs. The gap is conceptual, not computational.

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of B-cell leukaemias and lymphomas, with six FDA-approved products targeting CD19 or BCMA. Yet extending CAR-T to solid t...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were developed as blood glucose-lowering drugs for type 2 diabetes. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have since de...

Antimicrobial resistance (AMR) kills an estimated 1.27 million people annually and threatens to render routine surgeries and infections lethal again. The WHO has identified AMR as one of the top ten t...

Diagnosing Alzheimer's disease (AD) has historically required either invasive lumbar puncture for cerebrospinal fluid (CSF) analysis or expensive PET imaging (~$3,000–5,000 per scan). Both are impract...

The COVID-19 pandemic demonstrated that mRNA vaccines can be designed, manufactured, and deployed at unprecedented speed. Can this same platform be repurposed for cancer? Unlike infectious disease vac...

Chronic diseases (diabetes, heart failure, COPD, CKD) account for 74% of global deaths and consume ~86% of US healthcare spending (and a substantial majority of healthcare spending in high-income coun...

Non-alcoholic fatty liver disease — now renamed metabolic dysfunction-associated steatotic liver disease (MASLD) — affects ~30% of the global population and is the most common cause of chronic liver d...

Robotic surgical systems — led by Intuitive Surgical's da Vinci platform — have transformed minimally invasive surgery over the past two decades. But current systems are fundamentally teleoperated: th...

Approximately 30% of patients with major depressive disorder do not respond to two or more adequate antidepressant trials — a condition termed treatment-resistant depression (TRD). Psilocybin, the act...

~95% of the body's serotonin — the neurotransmitter targeted by SSRIs — is produced in the gut. The gut microbiome communicates with the brain through the vagus nerve, immune signalling (cytokines), a...

Drug development fails ~90% of the time in clinical trials, costing the industry ~$2 billion per approved drug. A primary reason: animal models poorly predict human toxicity and efficacy. Organ-on-chi...

Stem cell therapy promises to repair or replace damaged tissues across cardiovascular disease, neurodegeneration, bone defects, and autoimmune conditions. Mesenchymal stem cells (MSCs) have been the w...

*Clostridioides difficile* infection (CDI) is the leading cause of healthcare-associated infections in US hospitals, with 15–30% of patients experiencing recurrence after standard antibiotic treatment...

Chest X-rays are the most commonly performed diagnostic imaging study worldwide — an estimated ~2 billion X-ray examinations annually (encompassing various X-ray types; this is an approximate global f...

After curative-intent surgery for solid tumours, 20–50% of patients relapse — implying that microscopic cancer cells (minimal residual disease, MRD) persisted undetected. Conventional imaging cannot s...

Immune checkpoint inhibitors (ICIs) have transformed oncology — anti-PD-1/PD-L1 and anti-CTLA-4 antibodies produce durable responses in a subset of patients across many cancer types. But only 20–40% o...

The immune system can recognise and kill cancer cells — that's the basis of immunotherapy's success. Yet most cancers evade immune destruction through a combination of strategies: downregulating antig...

CAR-T cell therapy's success comes with a critical limitation: each product is manufactured from the individual patient's own T cells, requiring 2–4 weeks of production time and costing $300,000–500,0...

Melanoma, the deadliest skin cancer, has a ~100% five-year survival rate when detected at stage I but approximately 35% at stage IV (current SEER data, reflecting immunotherapy-era improvements). Earl...

CAR-T cell therapy has transformed treatment of blood cancers—achieving >80% complete remission in some B-cell leukemias. But against **solid tumors**, which account for >90% of cancer diagnoses, CAR-...

Depression affects over 300 million people globally, yet ~30% of patients don't respond to conventional antidepressants. The discovery that the gut harbors **95% of the body's serotonin** and communic...

Traditional single-cell RNA sequencing reveals *what* each cell expresses but destroys *where* it was. Spatial transcriptomics preserves both—measuring gene expression of thousands of genes while keep...

Semaglutide (Ozempic/Wegovy) has seen remarkably rapid adoption—but GLP-1 receptor agonists are far more than "weight loss drugs." The 2025 research landscape reveals a class of molecules with benefit...

Tissue biopsies are invasive, expensive, and capture only a snapshot of a single tumor site. **Liquid biopsies** analyze circulating tumor DNA (ctDNA) shed by tumors into the bloodstream, enabling can...

Over **100,000 people** are on organ transplant waiting lists in the US alone; 17 die daily waiting. The supply-demand gap widens every year. **Xenotransplantation**—transplanting gene-edited pig orga...

For people with ALS, locked-in syndrome, or severe stroke, the inability to speak is devastating—their thoughts are intact but trapped. **Brain-computer interfaces (BCIs)** that decode neural activity...

Developing a new drug from scratch takes **10–15 years and $2–3 billion**. Drug repurposing—finding new therapeutic uses for existing approved drugs—can reach patients in **3–5 years at a fraction of ...

A Phase 1 trial delivered CRISPR-Cas9 gene editing directly to the human liver, targeting ANGPTL3 to reduce triglycerides by 55% and LDL cholesterol by 49% from a single dose. This is the first in-human demonstration of in vivo CRISPR editing for cardiovascular disease.

Over 1,300 AI-enabled medical devices have received FDA clearance, with 258 added in 2025 alone. Yet clinical performance data exists for only about half of analyzed devices, and fewer than one-third report sex-specific outcomes.

Mendelian randomization studies are pushing the microbiome-depression relationship from correlational to causally upstream. A 2025 review in Frontiers in Immunology examines the evidence, identifies specific taxa signatures via machine learning, and maps emerging interventions from psychobiotics to CRISPR-modified gut bacteria.

A 40,703-participant Phase 3 trial across 11 countries reports that Moderna's mRNA-1010 influenza vaccine achieved 26.6% higher relative vaccine efficacy compared to a standard-dose flu shot in adults 50 and older—a statistically significant but clinically modest margin that raises questions about what 'better' means in seasonal vaccination.

Lecanemab's Phase 3 trial demonstrated a 1.75-point reduction in cognitive decline over 4 years—but with a 4.35x increase in ARIA risk compared to placebo. As donanemab gains FDA approval, the benefit-to-risk calculus is now a clinical reality that divides neurologists, patients, and payers.

Five patients now carry Neuralink implants, a UCL patient controlled a cursor the same day as surgery, and the FDA approved a new BCI clinical trial for speech restoration. Yet no brain-computer interface has been approved for general clinical use.

ASCO 2025 presented early-phase CAR-T data in solid tumors: 100% objective response in 3 mesothelioma patients at higher doses, 75% disease control in HER2+ breast cancer, and 14.6-month median overall survival in recurrent glioblastoma with B7H3-CART. The numbers are encouraging—and the sample sizes demand caution.

The SUMMIT trial found that tirzepatide, a dual GLP-1/GIP receptor agonist, reduced the composite of cardiovascular death or worsening heart failure by 38% in obese patients with HFpEF. This positions incretin-based therapy as a potential treatment for a condition with few effective options.

The FDA's rejection of MDMA-assisted therapy for PTSD in September 2025 sent shockwaves through the psychedelic medicine field. Phase 3 data showed significant PTSD symptom reduction, but trial design concerns—particularly around functional unblinding—proved decisive. What does this mean for psilocybin and the broader field?

A 2026 meta-analysis finds that fecal microbiota transplantation combined with immunotherapy yields a pooled 43% objective response rate. When FMT is paired with dual checkpoint blockade (anti-PD-1 + anti-CTLA-4), the response rate reaches 60%—compared to 37% for anti-PD-1 alone. The gut microbiome is emerging as a modifiable variable in cancer treatment.

In December 2025, the FDA approved oral semaglutide as the first GLP-1 pill for chronic weight management. The OASIS 4 trial reported 16.6% mean weight loss at 64 weeks versus 2.7% for placebo — shifting obesity pharmacotherapy from injectables toward oral access.

The first human trial of senolytic therapy in a pre-Alzheimer's population found dasatinib plus quercetin to be safe, with MoCA score improvements of 2.0 points in the most cognitively vulnerable participants. The study opens a new direction: treating neurodegeneration by clearing senescent cells.

Three-year follow-up from KEYNOTE-942 confirms that a personalized mRNA cancer vaccine (V940) combined with pembrolizumab reduced recurrence or death by 49% (HR 0.510) compared to immunotherapy alone in high-risk melanoma. Phase III enrollment is underway.

A 2025 review in the Journal of Clinical Investigation reports 77.2% clinical improvement and 61.3% bacterial eradication rates for phage therapy in multidrug-resistant infections. Combining phages with antibiotics increases eradication roughly 3x over phage monotherapy—but the FDA approval pathway remains the central unsolved problem.

A review in npj Digital Medicine examines how machine learning and deep learning integrate multi-omic, spatial pathology, and radiomic data to map tumor molecular pathways and guide treatment selection—moving precision oncology from genomic-only profiling toward genuinely multimodal decision-making.

A preprint reports SB000, a single-gene intervention that reverses epigenetic aging across multiple cell types with efficacy matching the four-factor Yamanaka cocktail — without triggering pluripotency. If confirmed, it could reframe cellular reprogramming therapeutics.

A deep learning model trained on 888 inpatient visits using continuous wearable vital signs predicted adverse clinical outcomes up to 17 hours in advance with 81.8% accuracy. Published in Nature Communications with prospective validation.

As of early 2025, 116 clinical trials using human pluripotent stem cell products have received regulatory approval, 83 distinct hPSC products are in development, and over 1,200 patients have been dosed—with no generalizable safety signals. The field is transitioning from proving that transplanted cells survive to proving that they repair.